XML 64 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Concentration Risk [Line Items]        
Revenue   $ 100,362 $ 57,489 $ 59,502
Accounts Receivable, net   798 13  
AbbVie Ireland Unlimited Company        
Concentration Risk [Line Items]        
Revenue $ 9,900 38,200 5,900 19,000
Major Customer        
Concentration Risk [Line Items]        
Revenue   91,753 53,618 51,777
Accounts Receivable, net   798 13  
Major Customer | AbbVie Ireland Unlimited Company        
Concentration Risk [Line Items]        
Revenue   38,192 5,878 18,997
Major Customer | Bristol Myers Squibb Company        
Concentration Risk [Line Items]        
Revenue   39,630 47,740 $ 32,780
Accounts Receivable, net     $ 13  
Major Customer | Astellas Pharma Inc.        
Concentration Risk [Line Items]        
Revenue   13,931    
Accounts Receivable, net   $ 798